- Marker has treated over 100 patients with their unique Multi TAA technology and so far has demonstrated strong efficacy in patients in AML, Lymphoma, Multiple Myeloma, and ALL.
- In lymphoma, 40% of treated patients, most of whom had at least 3-5 prior treatments and relapsed after a median of 4 months, have been in remission for 3+ years.
- The cost, simplicity, and efficacy of the treatment make it worthy of a share price that should easily be in excess of $100.00 when you look at the valuation of peers.
- The share price has been beaten up by day traders, but also due to incommunicative management that hasn't had a corporate presentation in 9 months to share past data.
For further details see:
Hey Redditors, Redirect Your Attention To Marker